What Happened?
, -based Stealth BioTherapeutics Appointed Robert Weiskopf as Chief Financial Officer
About the Company
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.
About the Person
Robert Weiskopf is Chief Financial Officer at Stealth BioTherapeutics. Previously, Robert held various senior HR leadership roles in the industry.
Info Source
News
Short Profile